cytosine and imatinib mesylate

cytosine has been researched along with imatinib mesylate in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Albitar, M; Beran, M; Cortes, JE; Faderl, S; Feldman, EJ; Giles, FJ; Kantarjian, HM; Larson, RA; Mamus, SW; O'Brien, SM; Roboz, GJ; Talpaz, M; Verstovsek, S	1
Beran, M; Cortes, J; Freireich, EJ; Giles, FJ; Golemovic, M; Gourdeau, H; Kantarjian, H; Orsolic, N; Verstovsek, S	1
Marx, A; Mayer, TU	1
Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A	1
Bekerman, E; Einav, S	1

Reviews

2 review(s) available for cytosine and imatinib mesylate

Article	Year
Five molecules we would take to a remote island. Chemistry & biology, 2010, Jun-25, Volume: 17, Issue:6 Topics: Benzamides; Cidofovir; Colchicine; Cytosine; Humans; Imatinib Mesylate; Organophosphonates; Piperazines; Pyrimidines; Tacrolimus; Vaccines, Synthetic	2010
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Current medicinal chemistry, 2011, Volume: 18, Issue:5 Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1	2011

Article

Year

Five molecules we would take to a remote island.

Chemistry & biology, 2010, Jun-25, Volume: 17, Issue:6

Topics: Benzamides; Cidofovir; Colchicine; Cytosine; Humans; Imatinib Mesylate; Organophosphonates; Piperazines; Pyrimidines; Tacrolimus; Vaccines, Synthetic

2010

Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.

Current medicinal chemistry, 2011, Volume: 18, Issue:5

Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1

2011

Trials

1 trial(s) available for cytosine and imatinib mesylate

Article	Year
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leukemia research, 2003, Volume: 27, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytosine; Dioxolanes; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy	2003

Article

Year

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.

Leukemia research, 2003, Volume: 27, Issue:12

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytosine; Dioxolanes; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy

2003

Other Studies

2 other study(ies) available for cytosine and imatinib mesylate

Article	Year
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. British journal of haematology, 2004, Volume: 124, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Survival; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Transplantation; Piperazines; Pyrimidines; Survival Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2004
Infectious disease. Combating emerging viral threats. Science (New York, N.Y.), 2015, Apr-17, Volume: 348, Issue:6232 Topics: Adenine; Adenosine; Antiviral Agents; Benzamides; Chloroquine; Communicable Diseases, Emerging; Cyclosporins; Cytosine; Dengue; Drug Approval; Drug Design; Erlotinib Hydrochloride; Hemorrhagic Fever, Ebola; Humans; Imatinib Mesylate; Indoles; Organophosphonates; Piperazines; Purine Nucleosides; Pyrimidines; Pyrroles; Pyrrolidines; Quinazolines; Sunitinib; Viruses	2015

Article

Year

Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.

British journal of haematology, 2004, Volume: 124, Issue:6

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Survival; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Transplantation; Piperazines; Pyrimidines; Survival Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2004

Infectious disease. Combating emerging viral threats.

Science (New York, N.Y.), 2015, Apr-17, Volume: 348, Issue:6232

Topics: Adenine; Adenosine; Antiviral Agents; Benzamides; Chloroquine; Communicable Diseases, Emerging; Cyclosporins; Cytosine; Dengue; Drug Approval; Drug Design; Erlotinib Hydrochloride; Hemorrhagic Fever, Ebola; Humans; Imatinib Mesylate; Indoles; Organophosphonates; Piperazines; Purine Nucleosides; Pyrimidines; Pyrroles; Pyrrolidines; Quinazolines; Sunitinib; Viruses

2015